白雲山(600332.SH):複方板藍根顆粒銷售預計不會對公司經營業績構成重大影響
格隆匯 10 月 18日丨白雲山(600332.SH)發佈公告,公司關注到在近日部分媒體關於白雲山複方板藍根顆粒體外研究結論的報道。就有關媒體報道,公司對相關情況進行了核實。
公告表示,廣州白雲山和記黃埔中藥有限公司(“白雲山和黃公司”)為公司持股50%的合營企業,不納入公司的合併範圍,公司對其採用長期股權投資的權益法進行核算。該公司主要從事中成藥生產銷售和藥品研發,主要產品包括板藍根顆粒、複方丹蔘片、複方板藍根顆粒等。
有關媒體報道所涉及的相關結論只是鍾南山院士團隊針對白雲山和黃公司複方板藍根顆粒開展的抗新型冠狀病毒體外篩選的實驗結果,後續還需對該產品開展進一步相關工作。
目前,板藍根產品在國內市場已是充分競爭的產品,板藍根顆粒、複方板藍根顆粒已獲批准的文號數量眾多,板藍根產品不是公司或其附屬企業的獨家生產品種。
目前,公司及下屬子公司、合營企業中僅有白雲山和黃公司生產和銷售板藍根產品。2019年,公司從白雲山和黃公司獲得的投資收益為人民幣6,796.03萬元,約佔公司當年利潤總額的1.65%;2020年上半年獲得的投資收益為人民幣3,599.82萬元,約佔公司當期利潤總額的1.59%。
白雲山和黃公司生產的複方板藍根顆粒2019年銷售收入約為人民幣10,910.07萬元,佔該公司當年銷售收入的7.23%;2020年上半年銷售收入約為人民幣7,554.61萬元,佔該公司同期銷售收入的8.35%。複方板藍根顆粒的銷售預計不會對公司的經營業績構成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.